Summary

Linagliptin may be a treatment option in patients with type 2 diabetes mellitus (T2DM) taking basal insulin, especially in those prone to hypoglycemia and/or declining renal function, according to results from a 52-week, multicenter, randomized, placebo-controlled, Phase 3 clinical trial.